Home / Business and Economy / AstraZeneca Beats Profit Estimates, Confirms 2030 Revenue Goal
AstraZeneca Beats Profit Estimates, Confirms 2030 Revenue Goal
27 Jul
Summary
- Second-quarter earnings exceeded expectations, boosting investor confidence.
- Company maintains 2026 guidance and $80 billion revenue target for 2030.
- Pipeline growth is strong with over twenty high-value readouts expected.
AstraZeneca announced second-quarter financial results that exceeded profit forecasts, reaffirming its commitment to its 2026 financial guidance. The company is on track to achieve its 2030 revenue ambition, targeting $80 billion annually.
Core earnings per share saw an 18% increase on a constant-currency basis, reaching $2.63. Total revenue grew 5% to $15.38 billion, slightly below analyst expectations. Net profit climbed over 2% year-on-year to $2.51 billion.
Sales of cancer drugs rose 15%, and rare disease revenues increased by 8%. However, the Chinese market experienced a 13% revenue decline due to generic competition and policy changes.
Despite a recent setback with nerve drug Wainua failing a late-stage trial, CEO Pascal Soriot expressed confidence in the company's pipeline, with more than twenty significant readouts anticipated within the next 18 months. AstraZeneca is also advancing its oral GLP-1 weight-loss candidate, elecoglipron, and has increased its peak sales projection for respiratory treatment tozorakimab.
Logistics and distribution expenses were noted to have increased due to the Iran war. AstraZeneca's stock saw a modest rise in London trading but remains down for the year.
